 webmaster@psych.uic.edu
|
Clinical
Profile of an Atypical Antipsychotic: Risperidone
John
A. Davis and Nancy Chen
Table
2. Interaction Effects between treatment and EPS variable
|
Antiparkinsonian
agent
|
F1,250
|
P-Value
|
| PANSS
Total |
0.859
|
0.355
|
| Negative
Symptoms Factor |
0.456
|
0.500
|
| Positive
Symptoms Factor |
0.871
|
0.352
|
| Disorganized
Thoughts Factor |
0.414
|
0.521
|
| Impulsivity/Hostility
Factor |
0.006
|
0.938
|
| Anxiety/Depression
Factor |
2.151
|
0.144
|
| Haloperidol-responsive |
1.303
|
0.255
|
| Haloperidol-nonresponsive |
0.430
|
0.513
|
| Serotonin-sensitive |
0.239
|
0.626
|
| Dopamine-sensitive |
1.670
|
0.197
|
|
Total
Parkinsonism
|
F1,250
|
P-Value
|
| PANSS
Total |
1.051
|
0.306
|
| Negative
Symptoms Factor |
2.124
|
0.146
|
| Positive
Symptoms Factor |
0.277
|
0.599
|
| Disorganized
Thoughts Factor |
0.231
|
0.631
|
| Impulsivity/Hostility
Factor |
0.687
|
0.408
|
| Anxiety/Depression
Factor |
1.827
|
0.178
|
| Haloperidol-responsive |
0.128
|
0.721
|
| Haloperidol-nonresponsive |
2.473
|
0.117
|
| Serotonin-sensitive |
0.723
|
0.396
|
| Dopamine-sensitive |
0.132
|
0.716
|
Two-way ANCOVA were
used to determine whether there are significant differences between
treatment (placebo, haloperidol, risperidone 2 mg, risperidone 6 mg,
and risperidone 10-16 mg) and EPS or use of antiparkinsonian agents.
No significant interaction effects were found indicating that the mean
EPS or use of antiparkinsonian agents differed significantly for the
different treatments.
|
